Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
Cara Therapeutics, Inc. (CARA)
Last cara therapeutics, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.caratherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi’s existing cash and Cara’s anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to host investor conference call and webcast today, December 18th, at 8:30am ET STAMFORD, Conn. and HOUSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) and Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focus
Show less
Read more
Impact Snapshot
Event Time:
CARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CARA alerts
High impacting Cara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CARA
News
- $TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – PWOD, CARA, NURO, VOXXGlobeNewswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARAPR Newswire
- CARA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cara Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire
- Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public ShareholdersBusiness Wire
- Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement [Yahoo! Finance]Yahoo! Finance
CARA
Earnings
- 11/14/24 - Beat
CARA
Sec Filings
- 12/20/24 - Form 425
- 12/20/24 - Form 8-K/A
- 12/18/24 - Form SCHEDULE
- CARA's page on the SEC website